blog

Alantra acts as buy-side advisor to illimity Bank in the acquisition of c.€240m non-performing exposures

8 August

Milan – Alantra, an independent global investment banking and asset management firm, has acted as buy-side advisor to Illimity Bank S.p.A, an Italian new-generation bank, in the acquisition of c.€240m non-performing exposures from Banca Monte dei Paschi di Siena S.p.A. (MPS), a leading Italian banking group. The transaction concerns the acquisition of a portfolio of non-performing loans (“NPLS”) owned […]

Alantra advises Kider Store Solutions on the acquisition of Grupo Caamaño

6 August

Alantra, an independent global investment banking and asset management firm, has advised Kider Store Solutions, a Spain-based company specialising in equipping commercial spaces for large-scale retail operators, on the acquisition of Grupo Caamaño, a Spain-based company focused on the development of integral projects for shopping centres and commercial spaces. Kider Store Solutions designs, manufactures and installs fitting solutions for stores and […]

Alantra advises LaSalle Capital on its sale of DeIorio Foods

5 August

BOSTON – Alantra, a leading global investment bank and asset management firm, is pleased to announce the sale of DeIorio Foods, Inc., a portfolio company of LaSalle Capital, L.P., to Rudolph Capital, LLC, an independent sponsor. The deal closed on July 18, 2019, and the value was not disclosed. Based in Utica, NY, DeIorio is a […]

Alantra advises Packaging Progressions, Inc. on its sale to The Middleby Corporation

30 July

Boston – Alantra, a leading global investment bank and asset management firm, is pleased to announce the sale of Packaging Progressions, Inc. (Pacproinc) to The Middleby Corporation (NASDAQ: MIDD), a global leader in the foodservice equipment industry. Alantra served as exclusive financial advisor to Pacproinc on this transaction, which closed on July 15, 2019 for an […]

Alantra acts as NOMAD and Global Coordinator in the IPO of Farmaè on the Italian AIM Market

29 July

Milan – Alantra, an independent global investment banking and asset management firm, has acted as NOMAD and Global Coordinator in the IPO on the Italian AIM of Farmaè, the leading online retailer of beauty & personal care products and OTC medications in Italy. With more than 200k active customers, 13mn site visits and 2.7mn products sold […]

Alantra advises St. James’s Place on expansion of its Partner Loan Securitisation Programme

24 July

London – Alantra, an independent global investment banking and asset management firm, has advised St. James’s Place plc (“SJP” or “the Company”) on a private placement of senior notes from its Partner Loan Securitisation Programme (“SJP Securitisation Programme”) in the UK. The senior variable rate notes (“SVNs”) carry a “AAA” rating from an external credit rating […]

Alantra advises Cinfa on the sale of 3P Biopharmaceuticals to Keensight Capital

24 July

Madrid – Alantra, an independent global investment banking and asset management firm, has advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European Growth Private Equity Fund with deep expertise in Healthcare. Founded in 2006 and based near Pamplona, Spain, 3P Biopharmaceuticals offers a complete biologics production […]

Alantra advises founders on the sale of pro optik to Paragon Partners

22 July

Frankfurt/Munich – Alantra, a leading global investment banking and asset management firm, has advised founders and Managing Directors Rainer Hildebrandt and Peter Hoppert on the sale of OC Office Consult GmbH & Co. KG, parent company of Germany’s third largest optician chain “pro optik” (hereinafter referred to as “pro optik”), to Paragon Partners GmbH and […]

Alantra advises Pharmamar in the sale of its two non-core business activities: Zelnova & Copyr

18 July

Madrid – Alantra, an independent global investment banking and asset management firm, has advised PharmaMar, a world leader company in the discovery of antitumor drugs of marine origin, on the sale of its 2 non-core business activities: Zelnova Zelita SA & Copyr SpA. PharmaMar is a company focused on oncology and committed to research and […]

Alantra enters venture capital via strategic partnership with Asabys Partners, a VC firm backed by Banc Sabadell

18 July

Barcelona / Madrid– Asabys Partners (“Asabys”), a Pan-European Venture Capital firm specialized in investments in the life sciences and health sectors, and Alantra, an investment banking and asset management firm, have reached an agreement by which Alantra becomes a strategic partner of Asabys through the acquisition of a 35% stake in the firm. The transaction […]